APRE: Aprea Projected Price to Earnings

Aprea Therapeutics (APRE) is developing ATR and WEE1 inhibitors to combat tumors, operating within a stable US environment free from geopolitical risks. The company's forward P/E ratio on GURU.Markets reflects a trend where the value of 0.00 aligns with the current metric. Business operations are based on ESG principles, strict waste disposal, and an ethical approach to patient data protection.

Projected Price to Earnings Ratio: aprea.com (APRE) for 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Aprea (APRE)

- stock value and consensus price forecast:

Price Chart Aprea Therapeutics|APRE - Price Target Chart

- market capitalization information:

Market Valuation Aprea Therapeutics Inc.|APRE - Value Adjusted for Debt and Cash

- issuer book value statistics:

Net Assets per Single Share Aprea Therapeutics|APRE - Total Stockholders' Equity|Market Value to Book Value Ratio aprea.com|APRE - Total Business Assets

- debt burden and liquidity indicators:

- company profitability and valuation multiples indicators:

APRE - Annual Net Income|Future Profit Aprea Therapeutics|APRE - Market Cap to Earnings|Projected Price to Earnings Aprea Therapeutics|APRE - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Aprea Therapeutics Inc.|APRE - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Aprea Therapeutics|APRE - Earnings per share for the trailing year|Quarterly EPS earnings growth aprea.com|APRE - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Aprea Therapeutics

- sales and revenue data:

APRE - Company Sales Revenue|Projected Sales Volume Aprea Therapeutics|APRE - P/S Multiple|Price-to-Projected Revenue Ratio Aprea Therapeutics Inc.

Analysis of all company metrics:APRE Aprea Therapeutics, Inc.

Aprea Therapeutics' strong reputation in the development of targeted anti-tumor drugs drives market expectations for the future monetization of its scientific discoveries. The ratio of the current share price to projected earnings allows for an assessment of the premium paid for growth potential, while the company's forward P/E trend serves as an indicator of the balance between investment optimism and the asset's actual fundamental value.

Competing companies